Targeting Folate Receptor-α in Gynecologic Cancers & other Solid Tumours with the Novel Antibody-Drug Conjugate, STRO-002

Time: 2:45 pm
day: Track C - Day 1 - PM

Details:

  • Review STRO-002 preclinical data (in vitro cytotoxicty and xenograft models) in ovarian, endometrial and other cancers
  • Evaluate clinical outcomes data from the STRO-002-GM1 dose escalation and expansion cohorts
  • Investigate ongoing clinical trials testing STRO-002 as a monotherapy and in combination with other agents

Speakers: